![]() ![]() Peter’s Hospitals NHS Foundation Trust, was devised to determine the clinical efficacy of NONS for the treatment of mild COVID-19 infection. This study, conducted by Dr Stephen Winchester and Dr Isaac John at Ashford and St. Combined with the roll-out of vaccines, NONS can help get the world back on its feet.”ĭouble-Blind, Placebo-Controlled, Phase 2 Clinical Trial - Details “The human toll of this disease cannot be expressed simply in numbers, and each day compounds the frustration, fear and loss suffered by millions around the world. ![]() Gilly Regev, CEO and co-founder of SaNOtize. “Now that NONS has been demonstrated to be safe and effective in clinical trials, we must move with urgency to get it into the hands of the public where it can help bring an end to the pandemic, accelerate a return to normality, and prevent future outbreaks of COVID-19 and its variants,” said Dr. The results of the UK trial corroborate the information gathered from SaNOtize’s earlier Phase 2 trials in Canada and independent lab tests at Utah State University’s Antiviral Research Institute. In addition to providing antiviral treatment in the early stages of infection and for those who have yet to be vaccinated, NONS has also demonstrated that it could also reduce infectivity – the frequency of transmission from an infected person to a non-infected person. The ease of NONS manufacture, storage and use makes NONS a treatment candidate that could soon be widely available at low-cost for long-term care facilities, healthcare and frontline workers, and the general population. Wide-scale equitable global availability of NONS could form a bridge during the global production and distribution of vaccines to help keep people safe and healthy. Swift approval and ramp-up of manufacturing could facilitate an almost immediate safe return to work, school and society, and spur an economic recovery that is months – if not years – ahead of full global vaccination. SaNOtize is applying to regulatory authorities in the UK and Canada for Emergency Use authorization. SaNOtize Seeking Emergency Use Authorization in UK and Canada The NO molecule released from NONS is identical to the one delivered in its gaseous form to treat persistent pulmonary hypertension, or Blue Baby Syndrome, in newborn babies. The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. ![]() It is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes COVID-19. ![]() The SaNOtize treatment is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs. Simply stated, I think this could be revolutionary.” Our trial included patients with a variant of concern and high viral loads yet still demonstrated significant reductions in the levels of SARS-CoV-2, which could be critical in supporting vaccines, preventing future outbreaks and safely reopening economies. “This simple portable nasal spray could be highly effective in the treatment of COVID-19 and reducing onward transmission. Stephen Winchester, Consultant Medical Virologist and Chief Investigator of this NHS Clinical Trial. “I expect this to be a major advance in the global battle against the devastating human impacts of the COVID-19 pandemic,” said Dr. Monoclonal antibodies are highly specific, expensive and must be administered intravenously in a clinical setting. NONS is the only novel therapeutic treatment so far proven to reduce viral load in humans that is not a monoclonal antibody treatment. There were no adverse health events recorded in the UK trial, or in over 7,000 self-administered treatments given in earlier Canadian clinical trials. The majority of these patients had been infected with the UK variant, which is considered a variant of concern. Within 72 hours, the viral load dropped by more than 99%. The average viral log reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95%. In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtize’s early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads. Biotech company SaNOtize Research & Development Corp., (SaNOtize), Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK, and Berkshire and Surrey Pathology Services, UK, today announced results of clinical trials indicating that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent the transmission of COVID-19, shorten its course, and reduce the severity of symptoms and damage in those already infected. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |